| Literature DB >> 18678489 |
Johan D Oslob1, Michael J Romanowski, Darin A Allen, Subramanian Baskaran, Minna Bui, Robert A Elling, William M Flanagan, Amy D Fung, Emily J Hanan, Shannon Harris, Stacey A Heumann, Ute Hoch, Jeffrey W Jacobs, Joni Lam, Chris E Lawrence, Robert S McDowell, Michelle A Nannini, Wang Shen, Jeffrey A Silverman, Michelle M Sopko, Bradley T Tangonan, Juli Teague, Josh C Yoburn, Chul H Yu, Min Zhong, Kristin M Zimmerman, Tom O'Brien, Willard Lew.
Abstract
This communication describes the discovery of a novel series of Aurora kinase inhibitors. Key SAR and critical binding elements are discussed. Some of the more advanced analogues potently inhibit cellular proliferation and induce phenotypes consistent with Aurora kinase inhibition. In particular, compound 21 (SNS-314) is a potent and selective Aurora kinase inhibitor that exhibits significant activity in pre-clinical in vivo tumor models.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18678489 DOI： 10.1016/j.bmcl.2008.07.073
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823